Enhancing graft-versus-leukemia after transplant: The rise of anti-cancer vaccines

Frontiers in Bioscience

Volumn 17, Issue 2, 2012, Pages 635-655

  Brusic, Ana ^a,b   Wu, Catherine J ^a,c,d  

^a HARVARD INSTITUTES OF MEDICINE   (United States)

^b MONASH UNIVERSITY   (Australia)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antigen Discovery; Cancer Vaccine; CD40L; CTLA 4; Defined Antigen; GM CSF; HSCT; Negative Immune Regulation; PD 1; Review; TLR agonists; Whole Cell

Indexed keywords

EID: 84860325514     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3949     Document Type: Article

References (145)

1. E. D. Thomas, H. L. Lochte, Jr., W. C. Lu and J. W. Ferrebee: Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med, 257(11), 491-6 (1957)
2. A. J. Peniket, M. C. Ruiz de Elvira, G. Taghipour, C. Cordonnier, E. Gluckman, T. de Witte, G. Santini, D. Blaise, H. Greinix, A. Ferrant, J. Cornelissen, N. Schmitz and A. H. Goldstone: An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant, 31(8), 667-78 (2003) (Pubitemid 36553477)
3. M. Ringhoffer, S. Harsdorf, M. Schmitt, M. Wiesneth, T. Zenz, S. Stilgenbauer, J. Greiner, K. Dohner, M. Marx, H. Dohner and D. Bunjes: Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse. Br J Haematol, 136(1), 127-30 (2007) (Pubitemid 44912598)
4. A. Deol and L. G. Lum: Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev, 36(7), 528-38
5. C. J. Wu and J. Ritz: Induction of tumor immunity following allogeneic stem cell transplantation. Adv Immunol, 90, 133-73 (2006) (Pubitemid 43765800)
6. C. D. Surh and J. Sprent: Regulation of mature T cell homeostasis. Semin Immunol, 17(3), 183-91 (2005) (Pubitemid 40488977)
7. K. Matsuoka, H. T. Kim, S. McDonough, G. Bascug, B. Warshauer, J. Koreth, C. Cutler, V. T. Ho, E. P. Alyea, J. H. Antin, R. J. Soiffer and J. Ritz: Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest, 120(5), 1479-93
8. E. P. Hochberg, A. C. Chillemi, C. J. Wu, D. Neuberg, C. Canning, K. Hartman, E. P. Alyea, R. J. Soiffer, S. A. Kalams and J. Ritz: Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. Blood, 98(4), 1116-21 (2001)
9. S. R. Lewin, G. Heller, L. Zhang, E. Rodrigues, E. Skulsky, M. R. van den Brink, T. N. Small, N. A. Kernan, R. J. O'Reilly, D. D. Ho and J. W. Young: Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood, 100(6), 2235-42 (2002) (Pubitemid 35001261)
10. E. Castermans, F. Baron, E. Willems, N. Schaaf-Lafontaine, N. Meuris, A. Gothot, J. F. Vanbellighen, C. Herens, L. Seidel, V. Geenen, R. Cheynier and Y. Beguin: Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning. Haematologica, 93(2), 240-7 (2008) (Pubitemid 351397712)
11. A. Lassaletta, M. Ramirez, J. M. Montero, M. Gonzalez-Vicent, A. Balas, L. Madero and M. A. Diaz: Full donor chimerism by day 30 after allogeneic peripheral blood progenitor cell transplantation is associated with a low risk of relapse in pediatric patients with hematological malignancies. Leukemia, 19(4), 504-6 (2005) (Pubitemid 40521151)
12. K. Talvensaari, E. Clave, C. Douay, C. Rabian, L. Garderet, M. Busson, F. Garnier, D. Douek, E. Gluckman, D. Charron and A. Toubert: A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation. Blood, 99(4), 1458-64 (2002) (Pubitemid 34547105)
13. A. Mullally and J. Ritz: Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood, 109(4), 1355-62 (2007) (Pubitemid 46239565)
14. C. J. Wu and J. Ritz: Revealing tumor immunity after hematopoietic stem cell transplantation. Clin Cancer Res, 15(14), 4515-7 (2009)
15. M. A. Cheever, J. P. Allison, A. S. Ferris, O. J. Finn, B. M. Hastings, T. T. Hecht, I. Mellman, S. A. Prindiville, J. L. Viner, L. M. Weiner and L. M. Matrisian: The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res, 15(17), 5323-37 (2009)
16. E. H. Warren, N. Fujii, Y. Akatsuka, C. N. Chaney, J. K. Mito, K. R. Loeb, T. A. Gooley, M. L. Brown, K. K. Koo, K. V. Rosinski, S. Ogawa, A. Matsubara, F. R. Appelbaum and S. R. Riddell: Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood, 115(19), 3869-78
17. K. V. Komanduri, L. S. St John, M. de Lima, J. McMannis, S. Rosinski, I. McNiece, S. G. Bryan, I. Kaur, S. Martin, E. D. Wieder, L. Worth, L. J. Cooper, D. Petropoulos, J. J. Molldrem, R. E. Champlin and E. J. Shpall: Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood, 110(13), 4543-51 (2007) (Pubitemid 351377822)
18. P. Mirmonsef, G. Tan, G. Zhou, T. Morino, K. Noonan, I. Borrello and H. I. Levitsky: Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation. Blood, 111(4), 2112-21 (2008) (Pubitemid 351451523)
19. L. Gattinoni, S. E. Finkelstein, C. A. Klebanoff, P. A. Antony, D. C. Palmer, P. J. Spiess, L. N. Hwang, Z. Yu, C. Wrzesinski, D. M. Heimann, C. D. Surh, S. A. Rosenberg and N. P. Restifo: Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med, 202(7), 907-12 (2005) (Pubitemid 41396891)
20. O. Alpdogan, J. M. Eng, S. J. Muriglan, L. M. Willis, V. M. Hubbard, K. H. Tjoe, T. H. Terwey, A. Kochman and M. R. van den Brink: Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood, 105(2), 865-73 (2005) (Pubitemid 40070777)
21. F. S. Hodi, M. Butler, D. A. Oble, M. V. Seiden, F. G. Haluska, A. Kruse, S. Macrae, M. Nelson, C. Canning, I. Lowy, A. Korman, D. Lautz, S. Russell, M. T. Jaklitsch, N. Ramaiya, T. C. Chen, D. Neuberg, J. P. Allison, M. C. Mihm and G. Dranoff: Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A, 105(8), 3005-10 (2008) (Pubitemid 351723658)
22. E. P. Alyea, D. J. DeAngelo, J. Moldrem, J. M. Pagel, D. Przepiorka, M. Sadelin, J. W. Young, S. Giralt, M. Bishop and S. Riddell: NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant, 16(8), 1037-69
23. E. Gilboa: The makings of a tumor rejection antigen. Immunity, 11(3), 263-70 (1999) (Pubitemid 29463234)
24. S. A. Rosenberg, J. C. Yang and N. P. Restifo: Cancer immunotherapy: moving beyond current vaccines. Nat Med, 10(9), 909-15 (2004) (Pubitemid 39273730)
25. M. Gannage, M. Abel, A. S. Michallet, S. Delluc, M. Lambert, S. Giraudier, R. Kratzer, G. Niedermann, L. Saveanu, F. Guilhot, L. Camoin, B. Varet, A. Buzyn and S. Caillat-Zucman: Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol, 174(12), 8210-8 (2005) (Pubitemid 40806333)
26. J. J. Molldrem, P. P. Lee, S. Kant, E. Wieder, W. Jiang, S. Lu, C. Wang and M. M. Davis: Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest, 111(5), 639-47 (2003) (Pubitemid 36278582)
27. B. D. Smith, Y. L. Kasamon, J. Kowalski, C. Gocke, K. Murphy, C. B. Miller, E. Garrett-Mayer, H. L. Tsai, L. Qin, C. Chia, B. Biedrzycki, T. C. Harding, G. H. Tu, R. Jones, K. Hege and H. I. Levitsky: K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res, 16(1), 338-47
28. J. Zhou, M. E. Dudley, S. A. Rosenberg and P. F. Robbins: Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 28(1), 53-62 (2005) (Pubitemid 40075938)
29. M. E. Dudley, J. Wunderlich, M. I. Nishimura, D. Yu, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, R. Sherry, S. F. Leitman and S. A. Rosenberg: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother, 24(4), 363-73 (2001) (Pubitemid 32825868)
30. T. Nishida, M. Hudecek, A. Kostic, M. Bleakley, E. H. Warren, D. Maloney, R. Storb and S. R. Riddell: Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin Cancer Res, 15(14), 4759-68 (2009)
31. W. A. Marijt, N. A. Kernan, T. Diaz-Barrientos, W. F. Veenhof, R. J. O'Reilly, R. Willemze and J. H. Falkenburg: Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation. Bone Marrow Transplant, 16(1), 125-32 (1995)
32. L. M. Faber, J. van der Hoeven, E. Goulmy, A. L. Hooftman-den Otter, S. A. van Luxemburg-Heijs, R. Willemze and J. H. Falkenburg: Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Clin Invest, 96(2), 877-83 (1995)
33. L. Gao, I. Bellantuono, A. Elsasser, S. B. Marley, M. Y. Gordon, J. M. Goldman and H. J. Stauss: Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood, 95(7), 2198-203 (2000) (Pubitemid 30167714)
34. T. Boon, P. G. Coulie, B. J. Van den Eynde and P. van der Bruggen: Human T cell responses against melanoma. Annu Rev Immunol, 24, 175-208 (2006)
35. P. van der Bruggen, C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth and T. Boon: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254(5038), 1643-7 (1991) (Pubitemid 21917508)
36. E. Goulmy: Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy. Cancer J, 10(1), 1-7 (2004) (Pubitemid 44313565)
37. Y. Takahashi, N. Harashima, S. Kajigaya, H. Yokoyama, E. Cherkasova, J. P. McCoy, K. Hanada, O. Mena, R. Kurlander, A. Tawab, R. Srinivasan, A. Lundqvist, E. Malinzak, N. Geller, M. I. Lerman and R. W. Childs: Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest, 118(3), 1099-109 (2008) (Pubitemid 351364617)
38. V. Lennerz, M. Fatho, C. Gentilini, R. A. Frye, A. Lifke, D. Ferel, C. Wolfel, C. Huber and T. Wolfel: The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A, 102(44), 16013-8 (2005) (Pubitemid 41552859)
39. J. Zhou, M. E. Dudley, S. A. Rosenberg and P. F. Robbins: Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother (1997), 28(1), 53-62 (2005) (Pubitemid 40075938)
40. J. Huang, M. El-Gamil, M. E. Dudley, Y. F. Li, S. A. Rosenberg and P. F. Robbins: T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol, 172(10), 6057-64 (2004) (Pubitemid 38621207)
41. A. M. Dudley, J. Aach, M. A. Steffen and G. M. Church: Measuring absolute expression with microarrays with a calibrated reference sample and an extended signal intensity range. Proc Natl Acad Sci U S A, 99(11), 7554-9 (2002) (Pubitemid 34568729)
42. M. Murata, E. H. Warren and S. R. Riddell: A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med, 197(10), 1279-89 (2003) (Pubitemid 36617774)
43. S. S. Tykodi, N. Fujii, N. Vigneron, S. M. Lu, J. K. Mito, M. X. Miranda, J. Chou, L. N. Voong, J. A. Thompson, B. M. Sandmaier, P. Cresswell, B. Van den Eynde, S. R. Riddell and E. H. Warren: C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients. Clin Cancer Res, 14(16), 5260-9 (2008)
44. C. J. Wu, X. F. Yang, S. McLaughlin, D. Neuberg, C. Canning, B. Stein, E. P. Alyea, R. J. Soiffer, G. Dranoff and J. Ritz: Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest, 106(5), 705-14 (2000)
45. R. Bellucci, C. J. Wu, S. Chiaretti, E. Weller, F. E. Davies, E. P. Alyea, G. Dranoff, K. C. Anderson, N. C. Munshi and J. Ritz: Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood, 103(2), 656-63 (2004) (Pubitemid 38140101)
46. U. Sahin, O. Tureci and M. Pfreundschuh: Serological identification of human tumor antigens. Current Opinion in Immunology, 9, 709-716 (1997) (Pubitemid 27485301)
47. K. S. Anderson and J. LaBaer: The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res, 4(4), 1123-33 (2005) (Pubitemid 41208670)
48. E. Jager, Y. Nagata, S. Gnjatic, H. Wada, E. Stockert, J. Karbach, P. R. Dunbar, S. Y. Lee, A. Jungbluth, D. Jager, M. Arand, G. Ritter, V. Cerundolo, B. Dupont, Y. T. Chen, L. J. Old and A. Knuth: Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A, 97(9), 4760-5 (2000) (Pubitemid 30238631)
49. R. Bellucci, E. P. Alyea, E. Weller, A. Chillemi, E. Hochberg, C. J. Wu, C. Canning, R. Schlossman, R. J. Soiffer, K. C. Anderson and J. Ritz: Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood, 99(12), 4610-7 (2002) (Pubitemid 34627234)
50. E. P. Alyea, R. J. Soiffer, C. Canning, D. Neuberg, R. Schlossman, C. Pickett, H. Collins, Y. Wang, K. C. Anderson and J. Ritz: Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood, 91(10), 3671-80 (1998) (Pubitemid 28225734)
51. M. A. Biernacki, O. Marina, W. Zhang, F. Liu, I. Bruns, A. Cai, D. Neuberg, C. M. Canning, E. P. Alyea, R. J. Soiffer, V. Brusic, J. Ritz and C. J. Wu: Efficacious Immune Therapy in Chronic Myelogenous Leukemia (CML) Recognizes Antigens That Are Expressed on CML Progenitor Cells. Cancer Res (2010)
52. O. Marina, U. Hainz, M. A. Biernacki, W. Zhang, A. Cai, J. S. Duke-Cohan, F. Liu, V. Brusic, D. Neuberg, J. L. Kutok, E. P. Alyea, C. M. Canning, R. J. Soiffer, J. Ritz and C. J. Wu: Serologic Markers of Effective Tumor Immunity against Chronic Lymphocytic Leukemia Include Nonmutated B-Cell Antigens. Cancer Res, 70(4), 1344-55 (2010)
53. M. Biernacki, A. Alonso, G. Zhang, L. Zhang, W. Zhang, Y. Tai, N. Munshi, E. P. Alyea, R. J. Soiffer, V. Brusic, J. Ritz, K. C. Anderson and C. J. Wu: DAPK2 and PIM1 are myeloma-associated antigens that elicit coordinated B and T cell immunity after syngeneic HSCT. In: 51st Annual Meeting of the American Society of Hematology. New Orleans, LA (2009)
54. C. J. Wu, M. Biernacki, J. L. Kutok, S. Rogers, L. Chen, X. F. Yang, R. J. Soiffer and J. Ritz: Graft-versusleukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Clin Cancer Res, 11(12), 4504-11 (2005) (Pubitemid 40825641)
55. R. Spisek, A. Kukreja, L. C. Chen, P. Matthews, A. Mazumder, D. Vesole, S. Jagannath, H. A. Zebroski, A. J. Simpson, G. Ritter, B. Durie, J. Crowley, J. D. Shaughnessy, Jr., M. J. Scanlan, A. O. Gure, B. Barlogie and M. V. Dhodapkar: Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med, 204(4), 831-40 (2007) (Pubitemid 46631612)
56. U. Hainz, O. Pozdnyakova, J. Aldridge, H. Kim, C. M. Canning, R. Soiffer, J. Ritz, E. P. Alyea and C. J. Wu: Effective graft-versus-leukemia responses to donor lymphocyte infusion are associated with preexisting CD8+ T cell marrow infiltrates. American Society for Blood and Marrow Transplantation, Feb 24-28, Orlando, FL; Biol Blood Marrow Transplant, 16(2), S310 (2010)
57. H. H. Lin, S. Ray, S. Tongchusak, E. Reinherz and V. Brusic: Evaulation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Bioinformatics, (in press) (2008)
58. Y. Ofran, H. T. Kim, V. Brusic, L. Blake, M. Mandrell, C. J. Wu, S. Sarantopoulos, R. Bellucci, D. B. Keskin, R. J. Soiffer, J. H. Antin and J. Ritz: Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. Clin Cancer Res, 16(5), 1642-51 (2010)
59. A. Cai, D. Keskin, A. Alonso, D. DeLuca, W. Zhang, N. Lokko, V. Nardi, R. M. Stone, J. Sidney, V. Brusic and C. J. Wu: Peptides Derived From Mutated BCR-ABL Elicit T Cell Immunity In CML Patients. In: 52nd Annual Society of Hematology Conference. (2010)
60. M. Deininger, E. Buchdunger and B. J. Druker: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood, 105(7), 2640-53 (2005) (Pubitemid 40446252)
61. X. F. Yang, C. J. Wu, L. Chen, E. P. Alyea, C. Canning, P. Kantoff, R. J. Soiffer, G. Dranoff and J. Ritz: CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res, 62(19), 5517-22 (2002)
62. X. F. Yang, C. J. Wu, S. McLaughlin, A. Chillemi, K. S. Wang, C. Canning, E. P. Alyea, P. Kantoff, R. J. Soiffer, G. Dranoff and J. Ritz: CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A, 98(13), 7492-7 (2001) (Pubitemid 32567976)
63. Y. W. Chu, S. Schmitz, B. Choudhury, W. Telford, V. Kapoor, S. Garfield, D. Howe and R. E. Gress: Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion. Blood, 112(7), 2836-46 (2008) doi:10.1182/blood-2008-04-149435
64. F. A. Flomerfelt, N. El Kassar, C. Gurunathan, K. S. Chua, S. C. League, S. Schmitz, T. R. Gershon, V. Kapoor, X. Y. Yan, R. H. Schwartz and R. E. Gress: Tbata modulates thymic stromal cell proliferation and thymus function. J Exp Med, 207(11), 2521-32 (2010)
65. K. M. Williams, P. J. Lucas, C. V. Bare, J. Wang, Y. W. Chu, E. Tayler, V. Kapoor and R. E. Gress: CCL25 increases thymopoiesis after androgen withdrawal. Blood, 112(8), 3255-63 (2008)
66. C. Sportes, F. T. Hakim, S. A. Memon, H. Zhang, K. S. Chua, M. R. Brown, T. A. Fleisher, M. C. Krumlauf, R. R. Babb, C. K. Chow, T. J. Fry, J. Engels, R. Buffet, M. Morre, R. J. Amato, D. J. Venzon, R. Korngold, A. Pecora, R. E. Gress and C. L. Mackall: Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med, 205(7), 1701-14 (2008) (Pubitemid 351962032)
67. Y. Levy, C. Lacabaratz, L. Weiss, J. P. Viard, C. Goujard, J. D. Lelievre, F. Boue, J. M. Molina, C. Rouzioux, V. Avettand-Fenoel, T. Croughs, S. Beq, R. Thiebaut, G. Chene, M. Morre and J. F. Delfraissy: Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest, 119(4), 997-1007 (2009)
68. C. Sportes, R. R. Babb, M. C. Krumlauf, F. T. Hakim, S. M. Steinberg, C. K. Chow, M. R. Brown, T. A. Fleisher, P. Noel, I. Maric, M. Stetler-Stevenson, J. Engel, R. Buffet, M. Morre, R. J. Amato, A. Pecora, C. L. Mackall and R. E. Gress: Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res, 16(2), 727-35
69. C. M. Rooney, C. A. Smith, C. Y. Ng, S. Loftin, C. Li, R. A. Krance, M. K. Brenner and H. E. Heslop: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet, 345(8941), 9-13 (1995)
70. C. M. Rooney, C. A. Smith, C. Y. Ng, S. K. Loftin, J. W. Sixbey, Y. Gan, D. K. Srivastava, L. C. Bowman, R. A. Krance, M. K. Brenner and H. E. Heslop: Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood, 92(5), 1549-55 (1998) (Pubitemid 28406858)
71. E. B. Papadopoulos, M. Ladanyi, D. Emanuel, S. Mackinnon, F. Boulad, M. H. Carabasi, H. Castro-Malaspina, B. H. Childs, A. P. Gillio, T. N. Small and et al.: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med, 330(17), 1185-91 (1994) (Pubitemid 24121987)
72. E. Orsini, E. P. Alyea, A. Chillemi, R. Schlossman, S. McLaughlin, C. Canning, R. J. Soiffer, K. C. Anderson and J. Ritz: Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. Biol Blood Marrow Transplant, 6(4), 375-86 (2000)
73. E. Orsini, E. P. Alyea, R. Schlossman, C. Canning, R. J. Soiffer, A. Chillemi, D. Neuberg, K. C. Anderson and J. Ritz: Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplant, 25(6), 623-32 (2000) (Pubitemid 30156587)
74. Y. Kondo, S. Shiobara and S. Nakao: Identification of T-cell clones showing expansion associated with graft-vsleukemia effect on chronic myelogenous leukemia in vivo and in vitro. Exp Hematol, 29(4), 471-6 (2001) (Pubitemid 32297671)
75. E. J. Claret, E. P. Alyea, E. Orsini, C. C. Pickett, H. Collins, Y. Wang, D. Neuberg, R. J. Soiffer and J. Ritz: Characterization of T cell repertoire in patients with graftversus-leukemia after donor lymphocyte infusion. J Clin Invest, 100(4), 855-66 (1997) (Pubitemid 27371704)
76. C. C. Davis, L. C. Marti, G. D. Sempowski, D. A. Jeyaraj and P. Szabolcs: Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation. Cancer Res, 70(13), 5249-58
77. M. Okas, J. Gertow, M. Uzunel, H. Karlsson, M. Westgren, K. Karre, O. Ringden, J. Mattsson and M. Uhlin: Clinical expansion of cord blood-derived T cells for use as donor lymphocyte infusion after cord blood transplantation. J Immunother, 33(1), 96-105
78. D. L. Porter, B. L. Levine, N. Bunin, E. A. Stadtmauer, S. M. Luger, S. Goldstein, A. Loren, J. Phillips, S. Nasta, A. Perl, S. Schuster, D. Tsai, A. Sohal, E. Veloso, S. Emerson and C. H. June: A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood, 107(4), 1325-31 (2006) (Pubitemid 43242365)
79. E. H. Warren, N. Fujii, Y. Akatsuka, C. N. Chaney, J. K. Mito, K. R. Loeb, T. A. Gooley, M. L. Brown, K. K. Koo, K. V. Rosinski, S. Ogawa, A. Matsubara, F. R. Appelbaum and S. R. Riddell: Therapy of relapsed leukemia after allogeneic hematopoietic cell transplant with T cells specific for minor histocompatibility antigens. Blood
80. W. A. Marijt, M. H. Heemskerk, F. M. Kloosterboer, E. Goulmy, M. G. Kester, M. A. van der Hoorn, S. A. van Luxemburg-Heys, M. Hoogeboom, T. Mutis, J. W. Drijfhout, J. J. van Rood, R. Willemze and J. H. Falkenburg: Hematopoiesis-restricted minor histocompatibility antigens HA-1-or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A, 100(5), 2742-7 (2003) (Pubitemid 36297569)
81. Cancer Research Institute. Cancer Vaccine Collaborative: Challenges. 2009; Available from: http://www.cancerresearch.org/Programs.aspx?id=3011.
82. B. G. Redman, A. E. Chang, J. Whitfield, P. Esper, G. Jiang, T. Braun, B. Roessler and J. J. Mule: Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J Immunother, 31(6), 591-8 (2008)
83. T. Tsuruma, F. Hata, T. Torigoe, T. Furuhata, S. Idenoue, T. Kurotaki, M. Yamamoto, A. Yagihashi, T. Ohmura, K. Yamaguchi, T. Katsuramaki, T. Yasoshima, K. Sasaki, Y. Mizushima, H. Minamida, H. Kimura, M. Akiyama, Y. Hirohashi, H. Asanuma, Y. Tamura, K. Shimozawa, N. Sato and K. Hirata: Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med, 2(1), 19 (2004)
84. D. Berd: M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Opin Biol Ther, 2(3), 335-42 (2002) (Pubitemid 34464814)
85. S. Li Volti, F. Di Gregorio, M. A. Romeo, A. Cannella, G. Pizzarelli, A. Sciacca and G. Russo: Immune status and the immune response to hepatitis B virus vaccine in thalassemic patients after allogeneic bone marrow transplantation. Bone Marrow Transplant, 19(2), 157-60 (1997) (Pubitemid 27068252)
86. P. Ljungman, V. Duraj and L. Magnius: Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant, 7(2), 89-93 (1991)
87. T. Onoe, H. Kalscheuer, M. Chittenden, G. Zhao, Y. G. Yang and M. Sykes: Homeostatic expansion and phenotypic conversion of human T cells depend on peripheral interactions with APCs. J Immunol, 184(12), 6756-65
88. B. Rocha, N. Dautigny and P. Pereira: Peripheral T lymphocytes: expansion potential and homeostatic regulation of pool sizes and CD4/CD8 ratios in vivo. Eur J Immunol, 19(5), 905-11 (1989) (Pubitemid 19165451)
89. K. Rezvani, M. Grube, J. M. Brenchley, G. Sconocchia, H. Fujiwara, D. A. Price, E. Gostick, K. Yamada, J. Melenhorst, R. Childs, N. Hensel, D. C. Douek and A. J. Barrett: Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood, 102(8), 2892-900 (2003) (Pubitemid 37248862)
90. C. Scheibenbogen, A. Letsch, E. Thiel, A. Schmittel, V. Mailaender, S. Baerwolf, D. Nagorsen and U. Keilholz: CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood, 100(6), 2132-7 (2002) (Pubitemid 35001248)
91. K. Rezvani, A. S. Yong, B. N. Savani, S. Mielke, K. Keyvanfar, E. Gostick, D. A. Price, D. C. Douek and A. J. Barrett: Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood, 110(6), 1924-32 (2007) (Pubitemid 47443906)
92. T. Kitawaki, N. Kadowaki, T. Kondo, T. Ishikawa, T. Ichinohe, S. Teramukai, M. Fukushima, Y. Kasai, T. Maekawa and T. Uchiyama: Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide-and keyhole-limpethemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia. Am J Hematol, 83(4), 315-7 (2008) (Pubitemid 351458011)
93. V. L. Reichardt, C. Y. Okada, A. Liso, C. J. Benike, K. E. Stockerl-Goldstein, E. G. Engleman, K. G. Blume and R. Levy: Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood, 93(7), 2411-9 (1999) (Pubitemid 29153646)
94. A. Liso, K. E. Stockerl-Goldstein, S. Auffermann-Gretzinger, C. J. Benike, V. Reichardt, A. van Beckhoven, R. Rajapaksa, E. G. Engleman, K. G. Blume and R. Levy: Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant, 6(6), 621-7 (2000)
95. R. S. Johnson, A. I. Walker and S. J. Ward: Cancer vaccines: will we ever learn? Expert Rev Anticancer Ther, 9(1), 67-74 (2009)
96. A. van Elsas, R. P. Sutmuller, A. A. Hurwitz, J. Ziskin, J. Villasenor, J. P. Medema, W. W. Overwijk, N. P. Restifo, C. J. Melief, R. Offringa and J. P. Allison: Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med, 194(4), 481-9 (2001) (Pubitemid 32835043)
97. E. Gilboa: The risk of autoimmunity associated with tumor immunotherapy. Nat Immunol, 2(9), 789-92 (2001) doi:10.1038/ni0901-789
98. A. Mackensen, B. Herbst, J. L. Chen, G. Kohler, C. Noppen, W. Herr, G. C. Spagnoli, V. Cerundolo and A. Lindemann: Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer, 86(3), 385-92 (2000) (Pubitemid 30187500)
99. J. Banchereau, A. K. Palucka, M. Dhodapkar, S. Burkeholder, N. Taquet, A. Rolland, S. Taquet, S. Coquery, K. M. Wittkowski, N. Bhardwaj, L. Pineiro, R. Steinman and J. Fay: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res, 61(17), 6451-8 (2001) (Pubitemid 32783251)
100. I. Borrello, E. M. Sotomayor, F. M. Rattis, S. K. Cooke, L. Gu and H. I. Levitsky: Sustaining the graftversus-tumor effect through posttransplant immunization with granulocyte-macrophage colonystimulating factor (GM-CSF)-producing tumor vaccines. Blood, 95(10), 3011-9 (2000) (Pubitemid 30321148)
101. S. Mundhada, J. Shaw, S. Mori, C. A. Savary and C. A. Mullen: Cellular tumor vaccines administered after T cell-depleted allogeneic bone marrow transplantation induce effective anti-tumor immune responses. Leuk Lymphoma, 46(4), 571-80 (2005) (Pubitemid 40584874)
102. T. Teshima, N. Mach, G. R. Hill, L. Pan, S. Gillessen, G. Dranoff and J. L. Ferrara: Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res, 61(1), 162-71 (2001) (Pubitemid 32095714)
103. J. S. Moyer, G. Maine and J. J. Mule: Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects. Biol Blood Marrow Transplant, 12(10), 1010-9 (2006)
104. L. Luznik, J. E. Slansky, S. Jalla, I. Borrello, H. I. Levitsky, D. M. Pardoll and E. J. Fuchs: Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood, 101(4), 1645-52 (2003) (Pubitemid 36182546)
105. V. T. Ho, M. Vanneman, H. Kim, T. Sasada, Y. J. Kang, M. Pasek, C. Cutler, J. Koreth, E. Alyea, S. Sarantopoulos, J. H. Antin, J. Ritz, C. Canning, J. Kutok, M. C. Mihm, G. Dranoff and R. Soiffer: Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A, 106(37), 15825-30 (2009)
106. U. Hainz, K. E. Stevenson, A. Alonso, N. R. Goldstein, N. Lokko, Q. Sievers, A. Brusic, W. Zhang, M. Pasek, W. Zeng, J. Choi, J. R. Brown, C. M. Canning, J. Koreth, C. Cutler, P. Armand, J. Antin, T. Sasada, J. Ritz, G. Dranoff, R. J. Soiffer, E. P. Alyea and C. J. Wu: Early post-transplant whole tumor cell vaccination elicits antitumor T cell responses in patients with advanced CLL. In: American Society for Bone Marrow Transplantation Meeting. Orlando, FL (2010)
107. G. Dranoff, E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll and R. C. Mulligan: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A, 90(8), 3539-43 (1993) (Pubitemid 23111402)
108. G. Parmiani, C. Castelli, L. Pilla, M. Santinami, M. P. Colombo and L. Rivoltini: Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol, 18(2), 226-32 (2007) (Pubitemid 46323086)
109. G. Dranoff: GM-CSF-based cancer vaccines. Immunol Rev, 188, 147-54 (2002) (Pubitemid 35398872)
110. I. Borrello and D. Pardoll: GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev, 13(2), 185-93 (2002) (Pubitemid 34229392)
111. G. Dranoff: GM-CSF-secreting melanoma vaccines. Oncogene, 22(20), 3188-92 (2003) (Pubitemid 36713771)
112. R. Soiffer, F. S. Hodi, F. Haluska, K. Jung, S. Gillessen, S. Singer, K. Tanabe, R. Duda, S. Mentzer, M. Jaklitsch, R. Bueno, S. Clift, S. Hardy, D. Neuberg, R. Mulligan, I. Webb, M. Mihm and G. Dranoff: Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte- macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol, 21(17), 3343-50 (2003) (Pubitemid 46606268)
113. K. Tani, M. Azuma, Y. Nakazaki, N. Oyaizu, H. Hase, J. Ohata, K. Takahashi, M. OiwaMonna, K. Hanazawa, Y. Wakumoto, K. Kawai, M. Noguchi, Y. Soda, R. Kunisaki, K. Watari, S. Takahashi, U. Machida, N. Satoh, A. Tojo, T. Maekawa, M. Eriguchi, S. Tomikawa, H. Tahara, Y. Inoue, H. Yoshikawa, Y. Yamada, A. Iwamoto, H. Hamada, N. Yamashita, K. Okumura, T. Kakizoe, H. Akaza, M. Fujime, S. Clift, D. Ando, R. Mulligan and S. Asano: Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol Ther, 10(4), 799-816 (2004) (Pubitemid 39272869)
114. E. M. Jaffee, R. H. Hruban, B. Biedrzycki, D. Laheru, K. Schepers, P. R. Sauter, M. Goemann, J. Coleman, L. Grochow, R. C. Donehower, K. D. Lillemoe, S. O'Reilly, R. A. Abrams, D. M. Pardoll, J. L. Cameron and C. J. Yeo: Novel allogeneic granulocyte-macrophage colonystimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol, 19(1), 145-56 (2001) (Pubitemid 32063491)
115. C. S. Higano, J. M. Corman, D. C. Smith, A. S. Centeno, C. P. Steidle, M. Gittleman, J. W. Simons, N. Sacks, J. Aimi and E. J. Small: Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer, 113(5), 975-84 (2008)
116. J. Nemunaitis, T. Jahan, H. Ross, D. Sterman, D. Richards, B. Fox, D. Jablons, J. Aimi, A. Lin and K. Hege: Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-smallcell lung cancer. Cancer Gene Ther, 13(6), 555-62 (2006)
117. B. Smith, Y. Kasamon, J. Kowalski, C. Gocke, K. Murphy, C. Miller, E. Garrett-Mayer, H. Tsai, L. Qin, C. Chia, B. Biedrzycki, T. Harding, G. Tu, R. Jones, K. Hege and H. Levitsky: K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate (2009)
118. P. Serafini, R. Carbley, K. A. Noonan, G. Tan, V. Bronte and I. Borrello: High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res, 64(17), 6337-43 (2004) (Pubitemid 39129439)
119. S. A. Hoption Cann, J. P. van Netten, C. van Netten and D. W. Glover: Spontaneous regression: a hidden treasure buried in time. Med Hypotheses, 58(2), 115-9 (2002) (Pubitemid 34174418)
120. D. E. Spaner, R. Foley, J. Galipeau and J. Bramson: Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies. Oncogene, 27(2), 208-17 (2008)
121. M. L. Salem, C. M. Diaz-Montero, S. A. El-Naggar, Y. Chen, O. Moussa and D. J. Cole: The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigenspecific responses upon their adoptive transfer into naive recipient mice. Vaccine, 27(4), 549-57 (2009)
122. B. Vasir, Z. Wu, K. Crawford, J. Rosenblatt, C. Zarwan, A. Bissonnette, D. Kufe and D. Avigan: Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells. J Immunol, 181(1), 808-21 (2008)
123. A. S. Lonsdorf, H. Kuekrek, B. V. Stern, B. O. Boehm, P. V. Lehmann and M. Tary-Lehmann: Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol, 171(8), 3941-6 (2003) (Pubitemid 37238666)
124. D. E. Speiser, D. Lienard, N. Rufer, V. Rubio-Godoy, D. Rimoldi, F. Lejeune, A. M. Krieg, J. C. Cerottini and P. Romero: Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest, 115(3), 739-46 (2005) (Pubitemid 40322250)
125. A. J. Van Den Eertwegh, R. J. Lensen, R. J. Scheper, G. Giaccone, C. J. Meijer, H. J. Bontkes, T. D. Gruijl and E. Hooiberg: Autologous tumor cell vaccination with PF-3512676 (CPG 7909) and GM-CSF followed by subcutaneous PF-3512676 and IFN-alpha for patients with metastatic renal cell carcinoma. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 24(18S (June 20 Supplement)), 2530 (2006)
126. N. Durakovic, V. Radojcic, M. Skarica, K. B. Bezak, J. D. Powell, E. J. Fuchs and L. Luznik: Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. Blood, 109(10), 4564-74 (2007) (Pubitemid 46743428)
127. B. R. Blazar, A. M. Krieg and P. A. Taylor: Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blood, 98(4), 1217-25 (2001)
128. Y. Lin, L. Zhang, A. X. Cai, M. N. Lee, D. Neuberg, C. M. Canning, R. J. Soiffer, N. Hacohen, E. P. Alyea, J. Ritz, T. K. Means and C. J. Wu: Effective anti-tumor immunity is associated with the development of TLRstimulating nucleic acid-immunoglobulin complexes in humans. J Clin Invest, In press (2011)
129. S. Dessureault, M. Alsarraj, S. McCarthy, T. Hunter, D. Noyes, D. Lee, J. Harkins, J. Seigne, R. Jennings and S. J. Antonia: A GM-CSF/CD40L producing cell augments anti-tumor T cell responses. J Surg Res, 125(2), 173-81 (2005) (Pubitemid 40602390)
130. G. Dotti, B. Savoldo, P. Yotnda, D. Rill and M. K. Brenner: Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cells. Blood, 100(1), 200-7 (2002) (Pubitemid 35177448)
131. R. F. Rousseau, E. Biagi, A. Dutour, E. S. Yvon, M. P. Brown, T. Lin, Z. Mei, B. Grilley, E. Popek, H. E. Heslop, A. P. Gee, R. A. Krance, U. Popat, G. Carrum, J. F. Margolin and M. K. Brenner: Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood, 107(4), 1332-41 (2006) (Pubitemid 43242366)
132. A. J. Korman, K. S. Peggs and J. P. Allison: Checkpoint blockade in cancer immunotherapy. Adv Immunol, 90, 297-339 (2006) (Pubitemid 43765802)
133. K. S. Peggs, S. A. Quezada, A. J. Korman and J. P. Allison: Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol, 18(2), 206-13 (2006) (Pubitemid 43327304)
134. F. S. Hodi, S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, W. Akerley, A. J. van den Eertwegh, J. Lutzky, P. Lorigan, J. M. Vaubel, G. P. Linette, D. Hogg, C. H. Ottensmeier, C. Lebbe, C. Peschel, I. Quirt, J. I. Clark, J. D. Wolchok, J. S. Weber, J. Tian, M. J. Yellin, G. M. Nichol, A. Hoos and W. J. Urba: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 363(8), 711-23 (2010)
135. A. Bashey, B. Medina, S. Corringham, M. Pasek, E. Carrier, L. Vrooman, I. Lowy, S. R. Solomon, L. E. Morris, H. K. Holland, J. R. Mason, E. P. Alyea, R. J. Soiffer and E. D. Ball: CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood, 113(7), 1581-8 (2009)
136. G. Q. Phan, J. C. Yang, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwartzentruber, N. P. Restifo, L. R. Haworth, C. A. Seipp, L. J. Freezer, K. E. Morton, S. A. Mavroukakis, P. H. Duray, S. M. Steinberg, J. P. Allison, T. A. Davis and S. A. Rosenberg: Cancer regression and autoimmunity induced by cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A, 100(14), 8372-7 (2003) (Pubitemid 36842552)
137. S. A. Quezada, K. S. Peggs, M. A. Curran and J. P. Allison: CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest, 116(7), 1935-45 (2006) (Pubitemid 44033317)
138. M. Ahmadzadeh, L. A. Johnson, B. Heemskerk, J. R. Wunderlich, M. E. Dudley, D. E. White and S. A. Rosenberg: Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood, 114(8), 1537-44 (2009)
139. S. Mumprecht, C. Schurch, J. Schwaller, M. Solenthaler and A. F. Ochsenbein: Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood, 114(8), 1528-36 (2009)
140. L. Carter, L. A. Fouser, J. Jussif, L. Fitz, B. Deng, C. R. Wood, M. Collins, T. Honjo, G. J. Freeman and B. M. Carreno: PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol, 32(3), 634-43 (2002) (Pubitemid 34257540)
141. J. A. Brown, D. M. Dorfman, F. R. Ma, E. L. Sullivan, O. Munoz, C. R. Wood, E. A. Greenfield and G. J. Freeman: Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol, 170(3), 1257-66 (2003) (Pubitemid 36139491)
142. S. Pilon-Thomas, A. Mackay, N. Vohra and J. J. Mule: Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol, 184(7), 3442-9
143. B. Li, A. Simmons, T. Du, C. Lin, M. Moskalenko, M. Gonzalez-Edick, M. VanRoey and K. Jooss: Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. Clin Immunol, 133(2), 184-97 (2009)
144. Q. Zhou, M. E. Munger, S. L. Highfill, J. Tolar, B. J. Weigel, M. Riddle, A. H. Sharpe, D. A. Vallera, M. Azuma, B. L. Levine, C. H. June, W. J. Murphy, D. H. Munn and B. R. Blazar: Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood, 116(14), 2484-93 (2010)
145. R. Berger, R. Rotem-Yehudar, G. Slama, S. Landes, A. Kneller, M. Leiba, M. Koren-Michowitz, A. Shimoni and A. Nagler: Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res, 14(10), 3044-51 (2008)